Literature DB >> 25804932

18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement.

Seol Hoon Park1, Jong Jin Lee2, Hye Ok Kim2, Dong Yun Lee2, Cheolwon Suh3, Hwoon-Yong Jung4, Kee Don Choi4, Do Hoon Kim4, Jooryung Huh5, Jin-Sook Ryu2.   

Abstract

The purpose of this study was to determine the 18F-FDG avidity of MALT lymphoma and the additional utility of 18F-FDG PET/CT in MALT lymphoma staging. Pretreatment 18F-FDG PET/CT scans of 222 patients with 227 MALT lymphoma lesions were retrospectively analyzed. 18F-FDG avidity of lesions was noted in 28%. The proportion was lower for gastric MALT lymphomas than for non-gastric lesions (9% vs. 60%, p<0.0001) and higher for mass-forming lesions than for superficial lesions (82% vs. 2%, p<0.0001). 18F-FDG PET/CT showed the presence of additional lesions in 23 patients: four of six true-positive lesions had 18F-FDG avid primary lesions, and 15 of 17 false-positive lesions had 18F-FDG-non avid lesions. 18F-FDG avidity differed according to the location and gross morphologic characteristics of the MALT lymphoma. Most gastric MALT lymphomas were superficial and had low 18F-FDG avidity. For staging, 18F-FDG PET/CT can be helpful mainly for 18F-FDG avid primary MALT lymphomas.

Entities:  

Keywords:  18F-FDG; Avidity; PET; lymphoma; mucosa-associated lymphoid tissue (MALT); staging

Mesh:

Substances:

Year:  2015        PMID: 25804932     DOI: 10.3109/10428194.2015.1030640

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

1.  18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.

Authors:  Domenico Albano; Mattia Bertoli; Paola Ferro; Federico Fallanca; Luigi Gianolli; Maria Picchio; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-12       Impact factor: 9.236

2.  Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI.

Authors:  Julian Kirchner; Cornelius Deuschl; Bernd Schweiger; Ken Herrmann; Michael Forsting; Christian Buchbender; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-22       Impact factor: 9.236

3.  Pulmonary mucosa-associated lymphoid tissue lymphoma: 18F-FDG PET/CT and CT findings in 28 patients.

Authors:  Domenico Albano; Andrea Borghesi; Giovanni Bosio; Mattia Bertoli; Roberto Maroldi; Raffaele Giubbini; Francesco Bertagna
Journal:  Br J Radiol       Date:  2017-10-03       Impact factor: 3.039

4.  A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.

Authors:  Zheng Wei; Jing Li; Zhixiang Cheng; Ling Yuan; Peng Liu
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

5.  Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma.

Authors:  Shunan Qi; May Y Huang; Yong Yang; Heiko Schöder; Sewit Teckie; Ariela Noy; Karen Chau; Joachim Yahalom
Journal:  Blood Adv       Date:  2018-03-27

6.  18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed?

Authors:  Julian Kirchner; Cornelius Deuschl; Johannes Grueneisen; Ken Herrmann; Michael Forsting; Philipp Heusch; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-04       Impact factor: 9.236

7.  CT, MRI, and 18F-FDG PET/CT Findings in Untreated Pulmonary and Hepatic B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Over a Five-Year Period: A Case Report.

Authors:  Aisheng Dong; Zhengguang Xiao; Jianmin Yang; Changjing Zuo
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  Mucosa-associated lymphoid tissue lymphoma with unusual 18F-FDG hypermetabolism arising at the colorectal anastomosis.

Authors:  Na-Sha Zhang; Fang Shi; Li Kong; Hui Zhu
Journal:  World J Gastroenterol       Date:  2017-01-21       Impact factor: 5.742

Review 9.  MRI and PET/MRI in hematologic malignancies.

Authors:  Marius E Mayerhoefer; Stephen J Archibald; Christina Messiou; Anton Staudenherz; Dominik Berzaczy; Heiko Schöder
Journal:  J Magn Reson Imaging       Date:  2019-07-01       Impact factor: 4.813

10.  Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients.

Authors:  Marius E Mayerhoefer; Chiara Giraudo; Daniela Senn; Markus Hartenbach; Michael Weber; Ivo Rausch; Barbara Kiesewetter; Christian J Herold; Marcus Hacker; Matthias Pones; Ingrid Simonitsch-Klupp; Leonhard Müllauer; Werner Dolak; Julius Lukas; Markus Raderer
Journal:  Clin Nucl Med       Date:  2016-02       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.